You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Investigational Drug Information for Lorecivivint


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Lorecivivint?

Lorecivivint is an investigational drug.

There have been 7 clinical trials for Lorecivivint. The most recent clinical trial was a Phase 3 trial, which was initiated on August 25th 2020.

The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and [disabled in preview]. The leading clinical trial sponsors are Biosplice Therapeutics, Inc., Samumed LLC, and [disabled in preview].

There are ten US patents protecting this investigational drug and ninety-nine international patents.

Recent Clinical Trials for Lorecivivint
TitleSponsorPhase
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)Biosplice Therapeutics, Inc.Phase 3
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the KneeBiosplice Therapeutics, Inc.Phase 3
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersBiosplice Therapeutics, Inc.Phase 1

See all Lorecivivint clinical trials

Clinical Trial Summary for Lorecivivint

Top disease conditions for Lorecivivint
Top clinical trial sponsors for Lorecivivint

See all Lorecivivint clinical trials

US Patents for Lorecivivint

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lorecivivint ⤷  Sign Up Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide Samumed, LLC (San Diego, CA) ⤷  Sign Up
Lorecivivint ⤷  Sign Up Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof Samumed, LLC (San Diego, CA) ⤷  Sign Up
Lorecivivint ⤷  Sign Up Treatment of osteoarthritis Samumed, LLC (San Diego, CA) ⤷  Sign Up
Lorecivivint ⤷  Sign Up Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-y- l)pyridin-3-yl)-3-methylbutanamide Samumed, LLC (San Diego, CA) ⤷  Sign Up
Lorecivivint ⤷  Sign Up Single-dose, ready-to-use injectable formulations Samumed, LLC (San Diego, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lorecivivint

Drugname Country Document Number Estimated Expiration Related US Patent
Lorecivivint Australia AU2017274350 2036-06-01 ⤷  Sign Up
Lorecivivint Brazil BR112018074725 2036-06-01 ⤷  Sign Up
Lorecivivint Canada CA3026076 2036-06-01 ⤷  Sign Up
Lorecivivint Chile CL2018003423 2036-06-01 ⤷  Sign Up
Lorecivivint Chile CL2021000611 2036-06-01 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.